info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
1
Oct
CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020
3
Sep
CymaBay Therapeutics to Present at Upcoming Investor Conferences
27
Aug
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020
20
Aug
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020
10
Aug
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
3
Aug
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
3
Aug
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
23
Jul
FDA Lifts All Clinical Holds on Seladelpar
19
Jun
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
5
Jun
Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020
<< Previous
1...
2
3
4
5
6
7
8
9
10
11
...26
Next >>
Show All
Scroll
